Gilead Sciences issues $3 billion in senior notes across four tranches

Gilead Sciences filed an underwriting agreement to issue $3 billion in senior notes with maturities ranging from 2028 to 2034 at rates between 4.250% and 4.900%. The debt offering provides capital financing and reflects investor demand for the biopharmaceutical company's credit.